Integra LifeSciences Holdings Corporation Announces Management Changes

Published: 2026-05-05 08:51:45 ET IART

Published on 05/05/2026 at 08:51 am EDT

Integra LifeSciences Holdings Corporation announced that Stuart M. Essig, chairman of Integra?s Board of Directors (Board), has been appointed president, effective May 1, 2026. Mr. Essig will continue to serve as chairman. He succeeds Mojdeh Poul who is pursuing other opportunities.

Mr. Essig brings more than thirty years of experience in the medical technology and healthcare industries and has deep familiarity with Integra, having served as chairman of the board since June 2012 and as a director since 1997. He previously served as Integra?s chief executive officer from 1997 through early 2012, and as its President from 1997 until 2010. Over the past two years, Mr. Essig has been actively engaged in the business through his executive chairman role, with direct involvement in key company priorities as well as operational and quality matters.

The company also announced that Michael McBreen, currently executive vice president, president, Codman Specialty Surgical, has been appointed chief commercial officer. As part of this leadership update, the Company also announced that Michael McBreen has been appointed chief commercial officer. In this newly created role, Mr. McBreen will help drive the next phase of Integra?s performance by further elevating the commercial organization and ensuring that customer and market-facing priorities are central to how the Company operates and makes decisions.

Both divisions and the entire global commercial structure will report to Mr. McBreen, with his appointment intended to strengthen revenue growth, customer outcomes, and execution across the business.